{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:43Z","timestamp":1790846143382,"version":"4.1.0"},"reference-count":152,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T00:00:00Z","timestamp":1450828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>Myeloproliferative neoplasms (MPN) are clonal stem cell diseases, first conceptualized in 1951 by William Dameshek, and historically included chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In 1960, Nowell and Hungerford discovered an invariable association between the Philadelphia chromosome (subsequently shown to harbor the causal<jats:italic>BCR\u2010ABL1<\/jats:italic>mutation) and CML; accordingly, the term MPN is primarily reserved for PV, ET, and PMF, although it includes other related clinicopathologic entities, according to the World Health Organization (WHO) classification system. In 2005, William Vainchenker and others described a Janus kinase 2 mutation (<jats:italic>JAK2<\/jats:italic>V617F) in MPN and this was followed by a series of additional descriptions of mutations that directly or indirectly activate JAK\u2010STAT:<jats:italic>JAK2<\/jats:italic>exon 12, myeloproliferative leukemia virus oncogene (<jats:italic>MPL<\/jats:italic>) and calreticulin (<jats:italic>CALR<\/jats:italic>) mutations. The discovery of these, mostly mutually exclusive, \u201cdriver\u201d mutations has contributed to revisions of the WHO diagnostic criteria and risk stratification in MPN. Mutations other than<jats:italic>JAK2<\/jats:italic>,<jats:italic>CALR<\/jats:italic>and<jats:italic>MPL<\/jats:italic>have also been described in MPN and shown to provide additional prognostic information. From the standpoint of treatment, over the last 50 years, Louis Wasserman from the Unites States and Tiziano Barbui from Italy had skillfully organized and led a number of important clinical trials, whose results form the basis for current treatment strategies in MPN. More recently, allogeneic stem cell transplant, as a potentially curative treatment modality, and JAK inhibitors, as palliative drugs, have been added to the overall therapeutic armamentarium in myelofibrosis. In the current review, I will summarize the important advances made in the last 10 years regarding the science and practice of MPN. Am. J. Hematol. 91:50\u201358, 2016. \u00a9 2015 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.24221","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:58:56Z","timestamp":1445554736000},"page":"50-58","source":"Crossref","is-referenced-by-count":146,"title":["Myeloproliferative neoplasms: A decade of discoveries and treatment advances"],"prefix":"10.1002","volume":"91","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_2_10_3_1","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the Blood","volume":"64","author":"Bennett JH.","year":"1845","journal-title":"Edinburgh Med Surg J"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01878089"},{"key":"e_1_2_10_5_1","article-title":"Sur une forme speciale de cyanose s'accompanant d'hyperglobulie excessive et peristente (On a special form of cyanosis accompanied by excessive and persistent erythrocytosis)","volume":"12","author":"Vaquez H.","year":"1895","journal-title":"Compt Rend Soc De Biol and Suppl Note Bull Et Mem Soc Med D'hop De Paris 3 ser"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-190308000-00001"},{"key":"e_1_2_10_7_1","first-page":"143","article-title":"A clinical lecture on erythraemia (polycythaemia with cyanosis, maladie de Vaquez)","volume":"1","author":"Osler W.","year":"1908","journal-title":"Lancet"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01891529"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.58.4.1468"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197610212951702"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V51.2.189.189"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow PJ","year":"1981","journal-title":"Blood"},{"key":"e_1_2_10_13_1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell PC","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_10_14_1","first-page":"1497.","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/315550a0"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132301"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3460176"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21645"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404069"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403902"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05764.x"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22663"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583161"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22058"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.606.606","article-title":"Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms","author":"Milosevic Feenstra JD","year":"2015","journal-title":"Blood"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.35"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23743"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.83"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-588426"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412098"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood.V124.21.157.157","article-title":"Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis","volume":"124","author":"Marty C","year":"2014","journal-title":"Blood"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537167"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567024"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407792111"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.119"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.286"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.163"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.64"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23585"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23617"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23694"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21543"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23554"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.163"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.148"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403279"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.148"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.5298"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-240135"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.234"},{"key":"e_1_2_10_72_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ajh.21574","article-title":"Transfusion\u2010dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis\u2010prognostic relevance is independent of IPSS or karyotype","volume":"85","author":"Tefferi A","year":"2009","journal-title":"Am J Hematol"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01373.x"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-320002"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.225"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405097"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216044"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.76"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.0310"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.57"},{"key":"e_1_2_10_83_1","first-page":"183","article-title":"Polycythemia Vera Study Group: A historical perspective","volume":"23","author":"Wasserman LR.","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035572"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208500"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_10_87_1","first-page":"460","article-title":"Ein betrag zur kentniss der symptmologie und therapie der primaren polycythemie","volume":"84","author":"Ludin M.","year":"1917","journal-title":"Z Klin Med"},{"key":"e_1_2_10_88_1","first-page":"322","article-title":"Zur Therapie der Polyzythaemie","volume":"32","author":"Eppinger H","year":"1918","journal-title":"Therap Monatshefte"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1933.00150230131005"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1148\/35.1.51"},{"key":"e_1_2_10_91_1","first-page":"856","article-title":"The treatment of polycythemia vera with lead compunds","volume":"203","author":"Falconer EH.","year":"1942","journal-title":"Am J Med"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-33-4-841"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1952.00240090100008"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1954.02950160021006"},{"key":"e_1_2_10_95_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.V13.8.757.757","article-title":"Therapy of polycythemia vera with myleran","volume":"13","author":"Wald N","year":"1958","journal-title":"Blood"},{"key":"e_1_2_10_96_1","first-page":"251","article-title":"Long\u2010range treatment of polycythemia vera with 6\u2010mercaptopurine","volume":"16","author":"Shullenberger CC.","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_10_97_1","first-page":"306.","article-title":"Evaluation of compund 8103 Abbott (N,N' bis (bromopropionyl) piperazine) in the treatment of polycythemia rubra vera","volume":"3","author":"Bond WH.","year":"1962","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_10_98_1","first-page":"499","article-title":"Polycythaemia Vera: Clinical studies on a series of 127 patients managed without radiation therapy","volume":"33","author":"Perkins J","year":"1964","journal-title":"Q J Med"},{"key":"e_1_2_10_99_1","first-page":"275","article-title":"Evaluation of haemopoiesis and comparative study of 32P and chlorambucil therapy by means of radiotracers in polycythemia vera","volume":"9","author":"Varela JE","year":"1965","journal-title":"Miner Nucl"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(66)90421-1"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-72-5-795_3"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V36.1.70.70"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.2246.121"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1962.tb07186.x"},{"key":"e_1_2_10_105_1","first-page":"166","volume-title":"Polycythemia Vera and the Myeloproliferative Disorders","author":"Berk PD","year":"1995"},{"key":"e_1_2_10_106_1","first-page":"17","article-title":"From efficacy to safety\u2014A polycythemia vera study group report on hydroxyurea in patients with polycythemia vera","volume":"34","author":"Fruchtman SM","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.89"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.233"},{"key":"e_1_2_10_109_1","article-title":"Revision of IPSET thrombosis","author":"Barbui Tea.","journal-title":"Blood Cancer J"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-591610"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.09.017"},{"key":"e_1_2_10_112_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-976165"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23895"},{"key":"e_1_2_10_114_1","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0792"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2152-7"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22026"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1401255"},{"key":"e_1_2_10_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087742"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531103"},{"key":"e_1_2_10_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395228"},{"key":"e_1_2_10_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"e_1_2_10_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1019-9"},{"key":"e_1_2_10_127_1","first-page":"126","volume-title":"Agnogenic Myeloid Metaplasia","author":"Silverstein MN.","year":"1975"},{"key":"e_1_2_10_128_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31815a7c0a"},{"key":"e_1_2_10_129_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_10_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21827"},{"key":"e_1_2_10_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_10_132_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_2_10_133_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6548"},{"key":"e_1_2_10_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23703"},{"key":"e_1_2_10_135_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"e_1_2_10_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22233"},{"key":"e_1_2_10_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.254"},{"key":"e_1_2_10_138_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.394.394","article-title":"Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)\u2010associated myelofibrosis with RBC\u2010transfusion\u2010dependence","volume":"122","author":"Tefferi A","year":"2013","journal-title":"Blood"},{"key":"e_1_2_10_139_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_10_140_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_10_141_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1109555"},{"key":"e_1_2_10_142_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_10_143_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_10_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.63"},{"key":"e_1_2_10_145_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13262"},{"key":"e_1_2_10_146_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.306"},{"key":"e_1_2_10_147_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.286"},{"key":"e_1_2_10_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.71"},{"key":"e_1_2_10_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.50"},{"key":"e_1_2_10_150_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"e_1_2_10_151_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503479"},{"key":"e_1_2_10_152_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310523"},{"key":"e_1_2_10_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-608315"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24221","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T23:03:22Z","timestamp":1718147002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,23]]},"references-count":152,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1002\/ajh.24221"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24221","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,23]]}}}